Pacira Pharma (PCRX): EXPAREL Sales Are Tracking Below Consensus - Wedbush

September 21, 2016 8:16 AM EDT
Get Alerts PCRX Hot Sheet
Price: $34.19 +0.50%

Rating Summary:
    11 Buy, 3 Hold, 1 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 13 | Down: 9 | New: 77
Trade PCRX Now!
Join SI Premium – FREE

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

Wedbush analyst, Liana Moussatos, reiterated her Outperform rating on shares of Pacira Pharmaceuticals (NASDAQ: PCRX) while noting that the Symphony Health EXPAREL estimated sales per day in August decreased -12% over July and total August sales tracked about -13.6% below consensus. Symphony Health sales and volume estimates for August were more than $21 million and 66-67 thousand pack units.

Combining July and August estimates, EXPAREL appears to be tracking about -7.6% below consensus. The September SH sales estimate is expected to be released on October 19.

No change to the price target of $109.

For an analyst ratings summary and ratings history on Pacira Pharmaceuticals click here. For more ratings news on Pacira Pharmaceuticals click here.

Shares of Pacira Pharmaceuticals closed at $40.37 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst EPS View

Related Entities

Liana Moussatos

Add Your Comment